Exacyl®
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Blood Loss After a Total Hip Replacement
Conditions
Blood Loss After a Total Hip Replacement
Trial Timeline
Oct 20, 2015 → Aug 29, 2017
NCT ID
NCT02403596About Exacyl®
Exacyl® is a phase 3 stage product being developed by Bayer for Blood Loss After a Total Hip Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT02403596. Target conditions include Blood Loss After a Total Hip Replacement.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02403596 | Phase 3 | Completed |
Competing Products
20 competing products in Blood Loss After a Total Hip Replacement
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + voriconazole | Astellas Pharma | Approved | 85 |
| Cefiderocol | Shionogi | Phase 2 | 52 |
| Bunazosin + Doxazosin + Valsartin | Eisai | Approved | 85 |
| Pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 65 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 65 |
| epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| Metoprolol Succinate + Hydrochlorothiazide | AstraZeneca | Phase 3 | 77 |
| AZD6140 + Placebo | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + moxifloxacin + Placebo | AstraZeneca | Phase 1 | 33 |
| MEDI-551 | AstraZeneca | Phase 1 | 33 |
| Ecallantide + Cyklokapron(R) | Merck | Phase 2 | 52 |
| Daptomycin | Merck | Phase 2 | 52 |
| ecallantide + placebo | Merck | Phase 2 | 52 |
| MK0859 | Merck | Phase 1 | 33 |
| Ecallantide + Placebo | Merck | Phase 2 | 52 |
| HSC835 | Novartis | Phase 2 | 52 |
| Aliskiren | Novartis | Approved | 85 |
| Aliskiren and HCTZ | Novartis | Approved | 85 |
| Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine | Novartis | Phase 2 | 52 |